178 related articles for article (PubMed ID: 2491867)
1. Plasminogen Activator Italian Multicenter Study (PAIMS): comparison of intravenous recombinant single-chain human tissue-type plasminogen activator (rt-PA) with intravenous streptokinase in acute myocardial infarction.
Magnani B
J Am Coll Cardiol; 1989 Jan; 13(1):19-26. PubMed ID: 2491867
[TBL] [Abstract][Full Text] [Related]
2. Thrombolysis in Myocardial Infarction (TIMI) Trial--phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase.
Rao AK; Pratt C; Berke A; Jaffe A; Ockene I; Schreiber TL; Bell WR; Knatterud G; Robertson TL; Terrin ML
J Am Coll Cardiol; 1988 Jan; 11(1):1-11. PubMed ID: 3121710
[TBL] [Abstract][Full Text] [Related]
3. A new thrombolytic regimen for acute myocardial infarction using combination half dose tissue-type plasminogen activator with full dose streptokinase: a pilot study. KAMIT Study Group.
Grines CL; Nissen SE; Booth DC; Branco MC; Gurley JC; Bennett KA; DeMaria AN
J Am Coll Cardiol; 1989 Sep; 14(3):573-80. PubMed ID: 2504797
[TBL] [Abstract][Full Text] [Related]
4. A prospective, randomized trial comparing combination half-dose tissue-type plasminogen activator and streptokinase with full-dose tissue-type plasminogen activator. Kentucky Acute Myocardial Infarction Trial (KAMIT) Group.
Grines CL; Nissen SE; Booth DC; Gurley JC; Chelliah N; Wolf R; Blankenship J; Branco MC; Bennett K; DeMaria AN
Circulation; 1991 Aug; 84(2):540-9. PubMed ID: 1907228
[TBL] [Abstract][Full Text] [Related]
5. Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge.
Chesebro JH; Knatterud G; Roberts R; Borer J; Cohen LS; Dalen J; Dodge HT; Francis CK; Hillis D; Ludbrook P
Circulation; 1987 Jul; 76(1):142-54. PubMed ID: 3109764
[TBL] [Abstract][Full Text] [Related]
6. New developments in thrombolytic therapy.
Collen D; Gold HK
Adv Exp Med Biol; 1990; 281():333-54. PubMed ID: 2129372
[TBL] [Abstract][Full Text] [Related]
7. A multicenter, randomized, placebo-controlled trial of a new form of intravenous recombinant tissue-type plasminogen activator (activase) in acute myocardial infarction.
Topol EJ; Morris DC; Smalling RW; Schumacher RR; Taylor CR; Nishikawa A; Liberman HA; Collen D; Tufte ME; Grossbard EB
J Am Coll Cardiol; 1987 Jun; 9(6):1205-13. PubMed ID: 2953770
[TBL] [Abstract][Full Text] [Related]
8. Effect of intravenous streptokinase as compared with that of tissue plasminogen activator on left ventricular function after first myocardial infarction.
White HD; Rivers JT; Maslowski AH; Ormiston JA; Takayama M; Hart HH; Sharpe DN; Whitlock RM; Norris RM
N Engl J Med; 1989 Mar; 320(13):817-21. PubMed ID: 2494454
[TBL] [Abstract][Full Text] [Related]
9. Increased serum levels of fibrinogen degradation products due to treatment with recombinant tissue-type plasminogen activator for acute myocardial infarction are related to bleeding complications, but not to coronary patency. European Co-operative Study Groups for rt-PA.
Arnold AE; Brower RW; Collen D; van Es GA; Lubsen J; Serruys PW; Simoons ML; Verstraete M
J Am Coll Cardiol; 1989 Sep; 14(3):581-8. PubMed ID: 2504798
[TBL] [Abstract][Full Text] [Related]
10. [Comparative randomized study of the effectiveness of intravenous recombinant tissue-type plasminogen activator and intravenous streptokinase in patients with acute myocardial infarct. Report of the European Cooperative Study Group for Recombinant Tissue-Type Plasminogen Activator].
Verstraete M; Bory M; Collen D; Erbel R; Lennane RJ; Mathey D; Michels HR; Schartl M; Uebis R; Bernard R
Klin Wochenschr; 1988; 66 Suppl 12():77-85. PubMed ID: 3126348
[TBL] [Abstract][Full Text] [Related]
11. Multicenter reperfusion trial of intravenous anisoylated plasminogen streptokinase activator complex (APSAC) in acute myocardial infarction: controlled comparison with intracoronary streptokinase.
Anderson JL; Rothbard RL; Hackworthy RA; Sorensen SG; Fitzpatrick PG; Dahl CF; Hagan AD; Browne KF; Symkoviak GP; Menlove RL
J Am Coll Cardiol; 1988 Jun; 11(6):1153-63. PubMed ID: 3284943
[TBL] [Abstract][Full Text] [Related]
12. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction.
GUSTO Angiographic Investigators
N Engl J Med; 1993 Nov; 329(22):1615-22. PubMed ID: 8232430
[TBL] [Abstract][Full Text] [Related]
13. Quantitative radionuclide assessment of regional ventricular function after thrombolytic therapy for acute myocardial infarction: results of phase I Thrombolysis in Myocardial Infarction (TIMI) trial.
Wackers FJ; Terrin ML; Kayden DS; Knatterud G; Forman S; Braunwald E; Zaret BL
J Am Coll Cardiol; 1989 Apr; 13(5):998-1005. PubMed ID: 2494246
[TBL] [Abstract][Full Text] [Related]
14. Comparative effects of APSAC and rt-PA on infarct size and left ventricular function in acute myocardial infarction. A multicenter randomized study.
Bassand JP; Cassagnes J; Machecourt J; Lusson JR; Anguenot T; Wolf JE; Maublant J; Bertrand B; Schiele F
Circulation; 1991 Sep; 84(3):1107-17. PubMed ID: 1909218
[TBL] [Abstract][Full Text] [Related]
15. Thrombolysis with intravenous human recombinant tissue-type plasminogen activator in acute myocardial infarction: the European experience.
de Bono DP
J Am Coll Cardiol; 1987 Nov; 10(5 Suppl B):75B-78B. PubMed ID: 2959717
[TBL] [Abstract][Full Text] [Related]
16. Streptokinase and recombinant tissue plasminogen activator (rt-PA) are equally effective in treating acute myocardial infarction.
Sherry S; Marder VJ
Ann Intern Med; 1991 Mar; 114(5):417-23. PubMed ID: 1899546
[TBL] [Abstract][Full Text] [Related]
17. Coronary thrombolysis: streptokinase or recombinant tissue-type plasminogen activator?
Collen D
Ann Intern Med; 1990 Apr; 112(7):529-38. PubMed ID: 2107781
[TBL] [Abstract][Full Text] [Related]
18. Thrombolytic versus fibrinogenolytic activity of rt-PA and streptokinase in patients with acute myocardial infarction.
Prisco D; Bonechi F; Scarti L; Tramontana M; Abbate R; Gensini GF
Angiology; 1990 Aug; 41(8):616-20. PubMed ID: 2117862
[TBL] [Abstract][Full Text] [Related]
19. New developments in thrombolytic therapy.
Collen DC; Gold HK
Thromb Res Suppl; 1990; 10():105-31. PubMed ID: 2180114
[TBL] [Abstract][Full Text] [Related]
20. A difference between front-loaded streptokinase and standard-dose recombinant tissue-type plasminogen activator in preserving left ventricular function after acute myocardial infarction (the Central Illinois Thrombolytic Therapy Study).
Taylor GJ; Moses HW; Koester D; Colliver JA; Katholi RE; Dove JT; Woodruff RC; Mikell FL; Becker LC; Sheehan FH
Am J Cardiol; 1993 Nov; 72(14):1010-4. PubMed ID: 8213579
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
